Subtopic Deep Dive

Synthetic Lethality in Chromatin Remodeling Cancers
Research Guide

What is Synthetic Lethality in Chromatin Remodeling Cancers?

Synthetic lethality in chromatin remodeling cancers exploits genetic vulnerabilities in tumors with mutations in SWI/SNF complex subunits like ARID1A, enabling selective killing via paralog dependencies or inhibitor combinations.

Researchers identify synthetic lethal partners through high-throughput screens targeting ARID1A-mutant cancers with ATR inhibitors (Williamson et al., 2016, 373 citations). SWI/SNF alterations occur in ~20% of malignancies, driving paralog vulnerabilities like SMARCA2 degradation via PROTACs (Hodges et al., 2016, 422 citations; Kofink et al., 2022, 193 citations). Over 10 key papers since 2011 detail mechanisms and therapeutic targets.

Curated Papers

Key Challenges

Why It Matters

Synthetic lethal strategies target SWI/SNF-deficient tumors selectively, sparing normal cells, as shown in ARID1A-mutant models sensitive to ATR inhibitors (Williamson et al., 2016). PROTAC-mediated SMARCA2 degradation validates paralog targeting in vivo for BRG1-mutant cancers (Kofink et al., 2022). These approaches inform clinical trials for chromatin remodeling-driven cancers, including ovarian and endometrial types with high ARID1A mutation rates (Hodges et al., 2016).

Key Research Challenges

Identifying paralog dependencies

Pinpointing synthetic lethal paralogs in polymorphic SWI/SNF complexes remains challenging due to subunit redundancy (Hodges et al., 2016). Screens must distinguish tumor-specific vulnerabilities from off-target effects (Kofink et al., 2022). Functional validation across cancer types is resource-intensive (Fernando et al., 2020).

Developing selective inhibitors

Creating inhibitors like ATR blockers or EZH2 antagonists selective for remodeler mutants faces toxicity hurdles (Williamson et al., 2016). PROTACs for SMARCA2 require optimization for oral bioavailability and in vivo efficacy (Kofink et al., 2022). Resistance mechanisms in SWI/SNF-altered tumors complicate translation (Hargreaves and Crabtree, 2011).

Overcoming tumor heterogeneity

SWI/SNF mutations vary across cancer subtypes, hindering universal synthetic lethal targets (Roy et al., 2014). Interplay with NuRD and Polycomb complexes adds regulatory complexity (Bracken et al., 2019). Patient-derived models are needed for personalized screening (Fernando et al., 2020).

Essential Papers

ATP-dependent chromatin remodeling: genetics, genomics and mechanisms

Diana C. Hargreaves, Robert H. Crabtree · 2011 · Cell Research · 896 citations

The Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer

H. Courtney Hodges, Jacob G. Kirkland, Robert H. Crabtree · 2016 · Cold Spring Harbor Perspectives in Medicine · 422 citations

During the last decade, a host of epigenetic mechanisms were found to contribute to cancer and other human diseases. Several genomic studies have revealed that ∼20% of malignancies have alterations...

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

Chris T. Williamson, Rowan Miller, Helen N. Pemberton et al. · 2016 · Nature Communications · 373 citations

A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells

Jovylyn Gatchalian, Shivani Malik, Josephine Ho et al. · 2018 · Nature Communications · 213 citations

Abstract The role of individual subunits in the targeting and function of the mammalian BRG1-associated factors (BAF) complex in embryonic stem cell (ESC) pluripotency maintenance has not yet been ...

Dangerous liaisons: interplay between SWI/SNF, NuRD, and Polycomb in chromatin regulation and cancer

Adrian P. Bracken, Gerard L. Brien, C. Peter Verrijzer · 2019 · Genes & Development · 201 citations

Changes in chromatin structure mediated by ATP-dependent nucleosome remodelers and histone modifying enzymes are integral to the process of gene regulation. Here, we review the roles of the SWI/SNF...

A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo

Christiane Kofink, Nicole Trainor, Barbara Mair et al. · 2022 · Nature Communications · 193 citations

Driver mutations of cancer epigenomes

David M. Roy, Logan A. Walsh, Timothy A. Chan · 2014 · Protein & Cell · 190 citations

Epigenetic alterations are associated with all aspects of cancer, from tumor initiation to cancer progression and metastasis. It is now well understood that both losses and gains of DNA methylation...

Reading Guide

Foundational Papers

Start with Hargreaves and Crabtree (2011, 896 citations) for SWI/SNF mechanisms; Roy et al. (2014) for epigenomic drivers establishing mutation context.

Recent Advances

Williamson et al. (2016) for ARID1A-ATR proof-of-concept; Kofink et al. (2022) for in vivo PROTAC validation; Fernando et al. (2020) for SMARCA4 variant impacts.

Core Methods

CRISPR knockout screens (Williamson et al., 2016); PROTAC degradation assays (Kofink et al., 2022); exome sequencing for variant function (Fernando et al., 2020).

How PapersFlow Helps You Research Synthetic Lethality in Chromatin Remodeling Cancers

Discover & Search

Research Agent uses searchPapers and citationGraph to map SWI/SNF synthetic lethality networks, starting from Williamson et al. (2016) on ARID1A-ATR vulnerability, then findSimilarPapers for paralog PROTACs like Kofink et al. (2022). exaSearch uncovers unpublished preprints on EZH2 blockers in ARID1A mutants.

Analyze & Verify

Analysis Agent applies readPaperContent to extract screen data from Williamson et al. (2016), verifies synthetic lethality claims with verifyResponse (CoVe), and runs PythonAnalysis for statistical validation of mutation frequencies using NumPy/pandas on SMARCA4 variants (Fernando et al., 2020). GRADE grading scores evidence strength for clinical translation.

Synthesize & Write

Synthesis Agent detects gaps in paralog targeting beyond SMARCA2 (Kofink et al., 2022) and flags contradictions in SWI/SNF roles (Hargreaves and Crabtree, 2011). Writing Agent uses latexEditText, latexSyncCitations for Hodges et al. (2016), and latexCompile to generate review manuscripts; exportMermaid visualizes lethality pathways.

Use Cases

"Analyze mutation selectivity in ARID1A synthetic lethal screens"

Analysis Agent → readPaperContent (Williamson et al., 2016) → runPythonAnalysis (pandas survival curves on mutant vs wild-type data) → GRADE-verified selectivity stats output.

"Draft LaTeX review on SMARCA2 PROTAC lethality"

Synthesis Agent → gap detection (Kofink et al., 2022) → Writing Agent → latexEditText (intro/methods) → latexSyncCitations (Hodges et al., 2016) → latexCompile → polished PDF review.

"Find code for SWI/SNF chromatin remodeling simulations"

Research Agent → paperExtractUrls (Hargreaves and Crabtree, 2011) → paperFindGithubRepo → githubRepoInspect → runnable Jupyter notebooks for nucleosome remodeling dynamics.

Automated Workflows

Deep Research workflow conducts systematic reviews of 50+ SWI/SNF papers: searchPapers → citationGraph (Hodges et al., 2016 hub) → structured synthetic lethality report. DeepScan applies 7-step analysis to Williamson et al. (2016): readPaperContent → CoVe verification → Python survival analysis. Theorizer generates hypotheses on NuRD-SWI/SNF interplay for new targets (Bracken et al., 2019).

Try Doxa for Synthetic Lethality in Chromatin Remodeling Cancers Research

Frequently Asked Questions

What defines synthetic lethality in chromatin remodeling cancers?

It refers to genetic interactions where SWI/SNF mutations like ARID1A create dependencies on paralogs or pathways like ATR, killable by inhibitors (Williamson et al., 2016).

What are key methods for identifying synthetic lethals?

High-throughput CRISPR screens in ARID1A-mutant cells identify ATR vulnerability; PROTAC screens target SMARCA2 in BRG1 mutants (Williamson et al., 2016; Kofink et al., 2022).

What are seminal papers?

Hargreaves and Crabtree (2011, 896 citations) on SWI/SNF mechanisms; Williamson et al. (2016, 373 citations) on ARID1A-ATR; Hodges et al. (2016, 422 citations) on BAF cancer roles.

What open problems exist?

Developing orally bioavailable PROTACs beyond SMARCA2; addressing resistance in heterogeneous SWI/SNF tumors; validating across rare variants (Kofink et al., 2022; Fernando et al., 2020).